Table 3.
Characteristics of MRI-based subtypes in the training and validation datasets.
| MRI-based subtypes | ||||||||
|---|---|---|---|---|---|---|---|---|
| Training dataset (N = 6322) | Validation dataset (N = 3068) | |||||||
| Cortex-led | NAWM-led | Lesion-led | p-Value | Cortex-led | NAWM-led | Lesion-led | p-Value | |
| Percentage of population | 43% (2697) | 32% (2011) | 25% (1614) | — | 42% (1279) | 21% (635) | 38% (1154) | — |
| Age ± SD | 43.03 ± 10.28 | 43.70 ± 11.05 | 43.60 ± 10.48 | NS | 41.72 ± 10.43 | 43.13 ± 11.28 | 44.07 ± 11.45 | NS |
| Female (%) | 63% | 63% | 65% | NS | 61% | 72% | 64% | NS |
| EDSS (IQR) | 4.0 (3.5) | 3.5 (3.0) | 4.5 (3.0) | <0.01 | 3.5 (3.5) | 3.5 (3.5) | 4.5 (3) | <0.01 |
| Disease duration | 6.27 (6.92) | 5.56 (6.82) | 9.09 (8.33) | <0.001 | 6.46 ± 8.49 | 7.2 ± 7.88 | 11.63 ± 10.72 | <0.001 |
| Lesion load (SD) | 18.05 (20.20) | 10.51 (12.35) | 47.88 (31.14) | <0.001 | 13.83 (13.8) | 8.81 (8.48) | 39.52 (27.2) | <0.001 |
| Lesion accrual in placebo arms (SE) | 1.02 (±0.31) | 0.88 (±0.41) | 2.64 (±1.50) | <0.01 | 1.57 (0.30) | 0.63 (0.12) | 2.41 (1.51) | <0.001 |
| Brain volume (SE) | 1119 (9.1) | 1092 (1.2) | 1089 (1.15) | <0.001 | 1117 (3.4) | 1120 (6.03) | 1077 (4.82) | <0.001 |
| Cortical volume (SE)* | 453.0 ± 1.7 | 476.60 ± 2.6 | 444.10 ± 2.8 | <0.001 | 455.81 ± 0.52 | 477.32 ± 0.83 | 453.10 ± 0.96 | <0.001 |
| Deep grey matter volume (SE) | 31.16 ± 0.04 | 32.97 ± 0.04 | 28.92 ± 0.07 | <0.001 | 31.47 ± 0.55 | 32.92 ± 0.08 | 29.33 ± 0.08 | <0.001 |
| Baseline SuStaIn stage (SE) | 14.54 ± 0.17 | 13.75 ± 0.13 | 16.15 ± 0.29 | <0.001 | 11.49 ± 0.19 | 10.31 ± 0.27 | 13.82 ± 0.29 | <0.001 |
| SuStaIn stage annual increase in placebo arms (SE) | 0.18 (±0.10) | 0.29 (±0.12) | 0.66 (±0.18) | <0.001 | 0.19 ± 0.21 | 0.12 ± 0.25 | 0.63 ± 0.15 | <0.001 |
IQR interquartile range, NAWM normal-appearing white matter, EDSS expanded disability status scale, SE standard error, SD standard deviation, NS non-significant, ml millilitre.